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1. Introduction
Rheumatoid arthritis (RA), an autoimmune disease of 
unknown etiology with systemic symptoms, especially 
involves joints and progresses with deformations (1). It has 
been reported that the prevalence of RA ranges from 0.5% 
to 1%. The disease is two to three times more common in 
women than in men (2).
As RA is a disease with systemic involvement, 
pain, increased depression level, and fatigue, as well as 
deteriorated quality of sleep and life, frequently accompany 
the involvement of the musculoskeletal and extraarticular 
systems (3–9). Pain is a frequent symptom in RA patients, 
and it generally progresses as chronic pain (3). Although its 
etiology is not exactly known, it is considered that fatigue in 
patients with RA is related to pain, disability, inflammation, 
psychosocial factors, and sleep disorders (6). Depression, 
also frequent in RA, has been found to be related to the level 
of fatigue and sleep disorders (7,10). Difficulty in falling 
asleep, increased frequency of waking during the night, and 
deteriorated sleep quality have been detected in patients 
with RA (8). It has been found that deteriorated sleep 
quality is related to pain, fatigue, and depression level (1). 
Pain, fatigue, and deteriorated sleep quality also negatively 
affect the quality of life of RA patients (9).
As has been reported, pain, increased depression 
level, fatigue, and deteriorated quality of sleep and life 
are frequent complaints in patients with RA, and these 
symptoms all affect and worsen each other. Various 
studies have evaluated these parameters in patients with 
RA, generally focusing on young populations. However, 
there are relatively few studies evaluating these symptoms 
in patients 65 years of age and over. Therefore, it would not 
be correct to generalize the results of these studies for all 
patients with RA, especially those aged 65 years and over. 
Background/aim: The aim of this study was to evaluate and determine the relationships (if any) among pain, depression levels, fatigue, 
sleep quality, and quality of life in patients with rheumatoid arthritis (RA) aged 65 years and over, and to compare the results with those 
of RA patients under 65 years of age. 
Materials and methods: The study included 52 patients with RA aged 65 years and over (Group 1) and 84 patients with RA under 
65 years of age (Group 2). Pain, depression levels, fatigue, sleep quality, quality of life, and disease activity of all of the participants 
were evaluated using a visual analog scale (VAS), the Beck Depression Inventory (BDI), the Checklist Individual Strength (CIS), the 
Pittsburgh Sleep Quality Index (PSQI), the Short Form-36 (SF-36), and the Disease Activity Score-28, respectively. 
Results: When the two groups were compared, higher scores for the VAS, BDI, total CIS, and PSQI were found in Group 1 compared 
to Group 2 (P = 0.003, P = 0.003, P = 0.007, and P = 0.001, respectively). The SF-36 subscales of the physical component summary and 
mental component summary were not statistically significantly different between the two groups (P > 0.05). 
Conclusion: This study evaluated the situation in elderly patients with RA and showed that pain, depression level, fatigue, and sleep 
quality worsen with age. 
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Given that life expectancy is now extended, knowing 
the frequency and severity of these parameters in patients 
aged 65 years and over is increasingly important for 
physicians in the treatment and follow-up of the disease. As 
such, the aim of this study was to evaluate and determine 
the relationships (if any) among pain, depression levels, 
fatigue, sleep, and quality of life in RA patients aged 65 
years and over, and to compare the results with those of 
RA patients under 65 years of age.
2. Materials and methods
2.1. Subjects
This study was conducted at a department of rheumatology 
from July 2013 to January 2014. Fifty-two subjects aged 
65 years and over and 84 subjects under 65 years of age, 
all diagnosed with RA according to the American College 
of Rheumatology 2010 criteria, were enrolled in the study 
by a rheumatologist (11). The patients were tested for 1-h 
erythrocyte sedimentation rate, C-reactive protein, complete 
blood count, renal and hepatic functions, rheumatoid factor, 
and thyroid function. Patients younger than 18 years; 
patients whose pain severity was 8 or more according to a 
visual analog scale (VAS) (12); patients with a pathology that 
could lead to joint pain, such as a fracture, joint dislocation, 
acute strain, or sprain; patients with inflammatory rheumatic 
diseases other than RA; patients who did not adhere to 
the RA drug therapy; patients taking antidepressants or 
anxiolytics; patients taking drugs that could affect sleep 
quality; patients with hypothyroidism; pregnant patients; 
patients with a history of stroke or malignancy; and patients 
with cognitive dysfunction who could not complete the 
study were excluded. Approval of the local ethics committee 
was provided. All of the participants were informed about 
the study and provided written consent.
2.2. Data collection
The age, sex, body mass index (BMI), working status, 
medical comorbidities, and current medications of all 
of the participants were recorded, as was duration of the 
disease. The participants were instructed not to exercise 
24 h before the second visit, so as not to influence the 
VAS, Checklist Individual Strength (CIS), Pittsburgh 
Sleep Quality Index (PSQI), and Disease Activity Score-28 
(DAS-28) scores. 
During the second visit, the pain level, depression 
level, fatigue level, sleep quality, quality of life, and disease 
activity of the participants were evaluated using the VAS, 
Beck Depression Inventory (BDI), CIS, PSQI, Short Form-
36 (SF-36) questionnaire, and DAS-28, respectively. The 
results were recorded by a researcher.
2.2.1. Assessment of pain severity
The VAS rates the pain of the individual on a 0–10 scale and 
is widely used in studies (13,14). Patients were evaluated in 
terms of pain with movement during the previous week.
2.2.2. Assessment of depression level
Depression levels were assessed by the BDI, which 
included 21 items with scores ranging from 0 to 3. The 
highest possible score is 63 points. The BDI, which is one 
of the most commonly used self-rated depression scales, 
can be adapted to every age group and is considered highly 
reliable (15). 
2.2.3. Assessment of fatigue
The CIS is a questionnaire with 20 items that can be scored 
on a seven-point Likert scale. The CIS is designed to assess 
different dimensions of fatigue: 1) the subjective experience 
of fatigue (eight items), 2) reduction in motivation (four 
items), 3) reduction in physical activity (three items), and 
4) reduction in concentration (five items). A total CIS 
score is obtained by summing the scores from the four 
dimensions. Higher scores indicate higher levels of fatigue, 
more concentration problems, less motivation, and low 
levels of physical activity (16,17). The total CIS score was 
evaluated in the present study.
2.2.4. Assessment of sleep quality
The PSQI was used for the assessment of sleep quality 
over a 1-month period. Nineteen individual items 
generated seven component scores, which were summed 
to produce a global score with a range of 0 to 21. Higher 
scores represented poorer subjective sleep quality. Sleep 
disturbance was classified as a PSQI score of >5 (18). 
2.2.5. Assessment of quality of life
The SF-36 is a generic health-related quality of life 
questionnaire employed to obtain scores for eight subscales, 
including physical function, role-physical, role-emotional, 
social functioning, general health, mental health, vitality, 
and bodily pain. These subscales are combined to form two 
higher-order summaries: the physical and mental health 
component summaries. Each subscale and each summary 
is reported on a 0–100 scale. Higher scores indicate better 
health-related quality of life (19).
2.2.6. Assessment of disease activity
Disease activity of RA patients was evaluated using the 
DAS-28 (20). For this purpose, tender joint count, swollen 
joint count, erythrocyte sedimentation rate, and global 
assessment score were used. According to the DAS-28 
scores, disease activity was defined to be in remission 
(≤2.4), with mild activity (>2.4 to <3.2), or with severe 
activity (>5.1).
2.3. Statistical analysis  
Data were analyzed using SPSS. Descriptive statistics for 
continuous variables are presented in the form of means and 
standard deviations, whereas categorical data are presented 
as numbers and percentages. Clinical data conforming to a 
normal distribution were compared using Student’s t-test. 
Nonparametric Mann–Whitney or chi-square tests were 
performed to compare sociodemographic and clinical 
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measures between the two groups. To determine linear 
associations between independent variables, Spearman’s 
rho correlation coefficients were calculated. For Spearman’s 
rho, correlations from 0 to 0.25 were considered as ‘no 
correlation’, 0.25 to 0.50 as a ‘mild/moderate correlation’, 
0.50 to 0.75 as a ‘strong correlation’, and 0.75 to 1.00 as a 
‘very strong correlation’. We considered a significance level 
of P < 0.05 to be statistically significant.
3. Results
Of 155 RA patients who were evaluated for inclusion in the 
study, 11 were excluded because they did not complete the 
questionnaire and eight were excluded because they did 
not want to answer the questions due to time constraints. 
Ultimately, the study was completed with a total of 136 
patients, including 52 patients aged 65 years or over 
(Group 1) and 84 patients under 65 years of age (Group 
2). The age ranges were 65–83 years in Group 1 and 23–64 
years in Group 2. The demographic characteristics of the 
two groups are shown in Table 1. 
The median disease duration was 120 months (range: 
6–480 months) in Group 1 and 72 months (range: 6–360 
months) in Group 2 (P > 0.05). The median DAS-28 scores 
were 2.78 (range: 0.54–5.9) in Group 1 and 2.41 (range: 
1.3–4.55) in Group 2 (P > 0.05). Comorbid diseases and 
medical treatments administered for RA in both groups 
are presented in Table 2.
When the two groups were compared, higher scores 
for the VAS, BDI (scores above 17 indicated depression), 
total CIS, and PSQI were found in Group 1 compared 
Table 1. Demographic characteristics of Group 1 and Group 2.
  Group 1  (n = 52)
Group 2 
(n = 84) P-value
Age, years (mean ± SD) 67.69 ± 4.33 45.71 ± 10.46 <0.001
Sex 0.244
Female 45 (86.5%) 66 (78.6%)
Male 7 (13.5%) 18 (21.4%)
BMI (mean ± SD) 28.22 ± 4.19 27.54 ± 4.29 0.365
Occupation 0.039
Housewife 42 (80.8%) 54 (64.3%) 
Civil servant 4 (7.7%) 21 (25%)
Work requiring physical effort 6 (11.5%) 9 (10.7%)  
SD: Standard deviation.
BMI: Body mass index.
Table 2. Comorbid diseases and medical treatment of Group 1 and Group 2. 
  Group 1 (n = 52)
Group 2  
(n = 84) P-value
Comorbid diseases <0.001
Diabetes mellitus 6 (11.5%) 5 (5.9%)
Hypertension 17 (32.8%) 5 (5.9%)
Coronary artery disease 1 (1.9%) 1 (1.1%)
Chronic obstructive pulmonary disease 0 1 (1.1%)
No comorbid diseases 28 (53.8%) 72 (86%)
Medical treatment 0.581
DMARD 49 (94.2%) 74 (88.1%)
TNF-alpha blockers 3 (5.8%) 10 (11.9%)  
DMARD: Disease-modifying antirheumatic drugs. 
TNF: Tumor necrosis factor.
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to Group 2 (P = 0.003, P = 0.003, P = 0.007, and P = 
0.001, respectively). The SF-36 subscales of the physical 
component summary and mental component summary 
were not statistically significantly different between the 
two groups (P > 0.05) (Table 3). 
The correlation analyses of the data from Group 1 and 
Group 2 are presented in Tables 4 and 5.
4. Discussion
In this study, RA patients aged 65 years or over had higher 
pain, higher depression level, increased fatigue, and worse 
sleep quality in comparison to matched RA patients under 
65 years of age; however, there was no significant difference 
between the two groups with respect to quality of life.   
Pain is a common RA symptom in every age group 
and the study by Jakobsson et al. suggested that the 
severity of pain increases with advanced age (21). 
Depression is another frequent symptom of RA, affecting 
more than 25% of patients (22). A study comparing the 
depression levels of RA patients aged 65 years or over and 
RA patients under 65 years reported a 36.9% frequency 
of depression in the older patients, whereas only 16% 
of the younger individuals had depressive moods (23). 
A study of 713 RA patients conducted by Wolfe and 
Hawley detected a higher level of depression in elderly 
patients (24). Fatigue is highly frequent in patients with 
RA, with the frequency of severe fatigue ranging from 
42% to 69% (25). The study by Nicassio et al. suggested 
that a model of increased disease activity, low mood, and 
poor sleep explains 62% of variance in RA fatigue (26). 
Deteriorated sleep quality, another frequent symptom 
of RA, is observed in more than half of patients (25,27). 
Sleep studies in patients with RA have revealed that 
interruptions in sleep are more frequent than changes 
in sleep phases. In addition, falling asleep takes longer 
for them, they wake up several times during the night 
and early in the morning, and they experience daytime 
sleepiness (5,28). Sleep difficulties have been in large part 
attributed to articular pain, depression, psychosocial 
stress and fatigue (29–31). This profile of sleep loss 
during part of the night, ubiquitous in those with RA, 
may result in a vicious cycle in which sleep disturbance 
activates clinical symptoms of mood and pain, which 
then contributes to further sleep loss (32). RA negatively 
affects the quality of life of patients. A study of RA patients 
aged 29–70 years detected extremely poor quality of life 
and showed that pain and problems with movements 
negatively affected quality of life (33).
Table 3. Comparison of Group 1 and Group 2 based on VAS, BDI, total CIS, PSQI, and SF-36 subscale scores.
  Group 1 (n = 52), mean ± SD
Group 2 (n = 84), 
mean ± SD P-value
VAS 4.42 ± 2.23 3.32 ± 1.92 0.003
BDI 16.44 ± 9.39 12.17 ± 7.24 0.003
Total CIS 94.59 ± 23 82.45 ± 26.42 0.007
PSQI 7.07 ± 4.21 5.01 ± 2.89 0.001
SF-36
Physical function 46.84 ± 26.50 55.05 ± 26.46 0.011
Role-physical (median, min–max) 0 (0–100) 25 (0–100) 0.178
Bodily pain 52.50 ± 24.80 42.73 ± 20.49 0.014
General health 54.42 ± 9.11 53.09 ± 10.52 0.454
Physical component summary 44.56 ± 12.48 46.74 ± 12.55 0.062
Vitality 53.65 ± 10.39 51.01 ± 11.24 0.173
Social function 45.43 ± 16.23 44.49 ± 13.49 0.716
Role-emotional (median, min–max) 0 (0–100) 33.3 (0–100) 0.075
Mental health 51.61 ± 12.80 52.61 ± 10.50 0.620
Mental component summary 46.81 ± 12.92 49.33 ± 12.77 0.267
SD: Standard deviation, VAS: Visual analog scale, BDI: Beck Depression Inventory, CIS: Checklist Individual 
Scale, PSQI: Pittsburgh Sleep Quality Index, SF-36: Short Form-36, min: minimum, max: maximum.
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This study supported all of the aforementioned studies, 
determining that pain, depression level, fatigue, and 
deteriorated quality of sleep were negatively affected in RA 
patients aged 65 years or over. In this study, the depression 
level and deteriorated sleep quality in RA patients aged 
65 years or over were 50% and 57.6%, respectively. When 
the depression level of elderly people was analyzed, it was 
determined that advanced patient age without RA also 
increases depression level (34). The depression level and 
deteriorated sleep quality are considerably higher in elderly 
patients with RA. Assessments of elderly patients with 
RA should thus focus on pain complaints, psychological 
problems, fatigue, and sleep patterns. It should also be 
kept in mind that advanced patient age without RA 
also influences depression level. However, there was no 
significant difference between the two groups with respect 
to quality of life. Although it was expected that a negative 
impact on the quality of life would increase as patients with 
RA aged and developed musculoskeletal diseases such as 
osteoarthritis and other comorbid diseases, the results of 
this study can be explained by the fact that patients accept 
and get used to this condition over time, considering 
their current condition to be good enough. Adaptation 
and acceptance on the part of patients also increase the 
chances of positive responses to treatment.
It is known that pain, increased depression level, 
fatigue, and deteriorated quality of sleep are highly 
frequent symptoms of RA, and many studies have shown 
that these parameters are interrelated, triggering and 
negatively affecting each other. Fatigue associated with RA 
is related to pain, inflammation, psychosocial factors, and 
sleep disorders, while depression is related to the level of 
fatigue and sleep disorders (6,7,10). A study comparing 
27 RA patients with healthy controls showed that sleep 
loss leads to an increase in the number of painful joints 
and severity of joint pain, as well as symptoms such as 
fatigue and anxiety (32). The present study also detected 
relationships among pain, depression level, fatigue, and 
quality of sleep within the two patient groups. Therefore, 
evaluation and correct treatment of these variables in 
patients with RA will help to end the vicious cycle of 
triggering each other and ensure more positive results in 
treatment and follow-up. 
There are several limitations to this study. First, the 
sample size was small, which may limit its applicability. 
Second, it was a cross-sectional study with no control 
group. Studies including a control group and long follow-
up periods might provide better guidance in terms of 
pain, depression level, fatigue, quality of sleep and life, 
influencing factors, and their long-term effects. Third, 
patients with fibromyalgia were not excluded. The presence 
of patients with fibromyalgia may also affect some of the 
parameters, such as pain, depression level, fatigue, and 
sleep quality. Finally, because the study was conducted 
at a single center, it cannot be generalized to the whole 
population, thus decreasing the strength of the study.
Due to developments in the treatment of RA, a great 
number of patients can live to advanced ages, and the 
frequency of RA starting in advanced age increases as 
life expectancy increases (35). Treatment and control of 
the disease become more complex in elderly RA patients. 
Many studies have evaluated pain, depression level, 
fatigue, sleep quality, and quality of life in patients with 
RA. Unlike most of those studies, which were conducted 
with young populations and whose results could not be 
generalized to all patients with RA, this study evaluated the 
situation in patients aged 65 years or over and showed that 
pain, depression level, fatigue, and sleep quality worsen 
with age. In other words, the treatment and follow-up of 
elderly patients with RA should focus on these parameters. 
However, multicenter studies with a greater number of 
elderly patients are required for more accurate data.
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